CSIR isolated the
hunger-suppressing chemical component in Hoodia Gordonii, now known as P57. Patented it, In
CSIR licensed the
UK-based firm Phytopharm to further develop and commercialize P57.
It has been established that P57
works fooling the brain into thinking it is full, even when it is not,
therefore curbing the appetite.
following year, Phytopharm licensed drug giant Pfizer to develop and
P57 (press releases from Phytopharm)
1997 23 June Phytopharm to
1998 24 August Collaboration with
Pfizer to Develop and Commercialize Obesity Drug (P57)
1998 13 October Anti-Obesity Drug
Candidate (P57) Enters Phase I Clinical Trials
1999 14 April Opens Manufacturing
unit in South Africa.
2000 03 August
Extension of Research Collaboration on Appetite Suppressant (P57) with
2001 07 March Commences Proof of
Principle Clinical Study of P57 for Obesity.
April Proof of Principle Phase I
Clinical Study of P57 for Obesity - Successful Completion of First
2001 05 July Proof of Principle
Clinical Study of P57 for Obesity - Successful Completion of Second
Stage 2001 10.
2001 05 December Successful
Completion of Proof of Principle Clinical Study of P57 for Obesity.
2002 11 April Opens new
manufacturing unit in South Africa.
2002 30 July Future development
2003 12 March Update on
development programme Appetite Suppressant P57
2003 30 July Pfizer returns
rights of P57.
our Certificate of Analysis here.